Request Trial

Pharma news

Reset all filters
Geography
Company
Refine search
WBD adds litigation firepower in Silicon Valley with DLA Piper veteran
Careers
WBD adds litigation firepower in Silicon Valley with DLA Piper veteran
Womble Bond Dickinson has expanded its West Coast footprint with the addition of a seasoned patent litigator, strengthening the firm’s life sciences capabilities amid rising IP disputes and rapid biotech innovation.   6 November 2025
US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Americas
US generics company wins patent battle over Merck Serono’s blockbuster MS drug
Merck Serono has failed to convince a US appeals court to overturn a PTAB decision invalidating two dosing regimen patents for cladribine.   4 November 2025
Novartis counsel warns: ‘Don’t let AI develop without our input’
Americas
Novartis counsel warns: ‘Don’t let AI develop without our input’
With AI reshaping IP enforcement, the pharma giant’s IP head warns that only active guidance will stop the industry from lagging behind, reports Muireann Bolger.   3 November 2025
Americas
Is Hatch-Waxman litigation for orphan drugs working?
Rising patent litigation over rare disease treatments highlights the success of the Hatch-Waxman and Orphan Drug Acts, says John Cox at Barnes & Thornburg.   31 October 2025
Americas
Novo Nordisk counters rival with $9bn bid for obesity drug developer
Danish pharma giant sweetens offer for hot peptide therapeutics company, aiming to cement its market position amid an intensifying GLP-1 patent race.   30 October 2025
Americas
The hidden code in life sciences deals
As IP plays a more important role in corporate valuations, acquirers are discovering that the biggest risks in life sciences deals aren’t always in the patents—they’re in the code, the algorithms, and the data. A panel at LSPN North America Fall shared why traditional due diligence is no longer enough.   27 October 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
Experts at LSPN North America Fall explore the often-overlooked factors that can make or break transactions, from employee retention strategies to cross-border patent standards.   23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
Parties impacted by exclusion orders need to carefully weigh their options for seeking clarity or rulings on redesigns, explain Daniel Muino and Charles Provine from Morrison Foerster.   23 October 2025
Americas
Less is more: patent lawyers flip the script after Amgen
The Supreme Court’s 2023 Amgen ruling turned patent strategy upside down. Now lawyers are rethinking everything they thought they knew about protecting inventions. Marisa Woutersen reports from LSPN North America–Fall.   22 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.   21 October 2025